Table 1. Per-protocol analysis pooled population CAPACITY studies 004 and 006: patient demographics
Pirfenidone# 2403 mg·day−1Placebo
CompleterNon-completerCompleterNon-completer
Patients %86.713.391.68.4
Baseline FVC % pred75.072.974.675.1
Baseline 6MWT m396388407377
  • CAPACITY: Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes; FVC: forced vital capacity; 6MWT: 6-min walk test. #: n = 345; : n = 347.